Decker et al. showed that reduction of PDGF signaling in MSCs by deletion of Pdgfra or by treatment with imatinib reduced myelofibrosis in the TPO overexpression model of MPN (9). This evidence concerns the gene PDGFRA and myeloproliferative disorder.